IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.

IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.

IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.

IDEXX Laboratories, Inc. (IDXX) Analyst/Investor Day Transcript

IDEXX Laboratories NASDAQ: IDXX outlined an innovation-led growth strategy at its 2026 Investor Day, highlighting a $45 billion global companion-animal testing opportunity, expanded commercial investments and a pipeline of diagnostic, software and artificial-intelligence offerings intended to increase testing utilization in veterinary practices.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces Catalyst™ proBNP Test, the first and only dual-species, in-clinic diagnostic assay for cardiac assessment.

IDEXX Laboratories remains a buy, supported by a durable moat, strong recurring revenue, and a long-term international growth runway. Recent Q2 2026 results showed 9% organic revenue growth, EPS guidance raised to $14.69–14.94, and robust expansion of diagnostic offerings. Installed base growth for core machines is moderating in the US but remains early-stage internationally, underpinning multi-decade expansion potential.

Aurora Investment Managers LLC. bought a new stake in IDEXX Laboratories, Inc. (NASDAQ: IDXX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 4,638 shares of the company's stock, valued at approximately $2,442,000. IDEXX Laboratories comprises approximately 1.5%

Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.